separately , under the terms of the joint venture agreement , yuhan contributed an initial investment of $ 10.0 million to immuneoncia , and we granted immuneoncia an exclusive license to one of our immune checkpoint antibodies for specified countries while retaining the rights for the u.s. , european and japanese markets , as well as global rights for immuneoncia to two additional antibodies that will be selected by immuneoncia from a group of pre-specified antibodies from our immuno-oncology antibody portfolio . yuhan owns 51 % of immuneoncia , while we own 49 % . 3sbio term sheet in june 2016 , we and tnk entered into a binding term sheet with shenyang sunshine pharmaceutical company ltd ( “ 3sbio ” ) , a china based company , to form a joint venture to develop and commercialize proprietary immunotherapies , including those developed from , including or using tnk 's car-t technology targeting cea positive cancers . due diligence and negotiations between 3sbio and us for the definitive agreement ( s ) are currently ongoing . in june 2016 , 3sbio purchased $ 10.0 million of common stock and warrants as part of our private placement offering . servier license and collaboration agreement in july 2016 , we announced a license and collaboration agreement with les laboratoires servier , sas , a corporation incorporated under the laws of france , and institut de recherches internationales servier , a company duly organized and existing under the laws of france ( individually and collectively , “ servier ” ) for the development , manufacture and commercialization of products using our fully human immuno-oncology anti-pd-1 mab sti-a1110 . the financial terms of the agreement include , among other things , a non-refundable upfront payment to sorrento of 25 million , or $ 27.4 million , which we received in july 2016. we may also receive development milestone payments for the initial product and each additional product . we may receive up to 710 million in various payments based on commercial sales milestones related to annual net sales levels for the initial product and then also for each additional product . in addition to the commercial sales milestones , we will be entitled to receive variable royalties on the sales of all commercialized products ranging from high single-digit to double-digit percentages . during the twelve months ended december 31 , 2016 , we recognized $ 3.8 million in license fee revenue pursuant to the agreement . cha biotech term sheet in august 2016 , we announced a binding term sheet to create a joint venture ( the “ jv ” ) with cha biotech co. , ltd. ( “ cbt ” ) of south korea to develop and commercialize proprietary car modified cellular therapies based on cbt 's activated killer cell ( “ akc ” ) technology in combination with five of our cars for all disease conditions , including oncology and infectious diseases . the jv will cover products on a global basis with the exception of the greater chinese market , which includes mainland china , hong kong , macau and taiwan . in addition , we will obtain an exclusive license to develop and commercialize cbt 's novel investigator-initiated trial stage akc technology in major territories , including the united states and europe , and with a co-exclusive license in china . under the terms of the term sheet , we and cbt will make contributions of $ 2 million to the jv , and we will grant the jv an 51 exclusive license to five cars solely for combination with the akc technology , while cbt will contribute its akc technology . cbt will initi ally own 51 % of the jv while we will initially hold the remaining 49 % . we , under a royalty bearing license , will also gain access to the akc technology for the use outside the jv alone or with any other of our product candidates . due diligence and negotiat ions between cbt and us for the definitive agreement ( s ) are currently ongoing . however , the binding term sheet is currently terminable by either party at will and no assurances can be made that the transaction will be completed . scilex acquisition on november 8 , 2016 , we entered into a stock purchase agreement with scilex pharmaceuticals inc. ( “ scilex ” ) and a majority of the stockholders of scilex ( the “ scilex stockholders ” ) pursuant to which we acquired from the scilex stockholders approximately 72 % of the outstanding capital stock of scilex . scilex 's lead product candidate , ztlido , is a next-generation lidocaine patch currently in development for the treatment of postherpetic neuralgia ( “ phn ” ) , a severe neuropathic pain condition . ztlido is manufactured by our collaboration partner in their state of the art manufacturing facility . celularity transaction in november 2016 , we entered into a non-binding term sheet between us , our subsidiary , tnk , and celularity , inc. ( “ celularity ” ) , a research and development company , setting forth the terms and conditions by which we or tnk with one or more third parties would contribute certain assets to celularity ( the “ celularity transaction ” ) . in addition , at this time , we loaned $ 5.0 million to celularity pursuant to a promissory note issued to us ( the “ celularity note ” ) . pursuant to the terms of the celularity note , the loan will be due and payable in full on the earlier of november 1 , 2017 and the occurrence of an event of default under the celularity note ( the “ maturity date ” ) . the celularity note also provides that , in certain circumstances , we shall loan celularity up to an additional $ 5.0 million over the next 12 months . story_separator_special_tag gain on derivative liability for the year ended december 31 , 2016 was $ 5,520 thousand compared to a loss on derivative liability of $ 3,360 thousand for the year ended december 31 , 2015. the increase in the year ended december 31 , 2016 as compared to the same period in 2015 is due to the expiration of the unexercised derivative liability on march 31 , 2016 associated with the cancelled call option on shares of nantkwest , inc. stock . gain or loss on equity investments . gain on equity investments for the year ended december 31 , 2016 was $ 435 thousand compared to a loss on equity investments of $ 4,041 thousand for the year ended december 31 , 2015. the increase was primarily due to the recognition of our portion of the loss from operations from our joint venture entities which did not exist during the same period in 2015. interest expense . interest expense for the years ended december 31 , 2016 and 2015 was $ 1,610 thousand and $ 1,652 thousand , respectively . interest income . interest income for the years ended december 31 , 2016 and 2015 was $ 272 thousand and $ 24 thousand , respectively . the increase in interest income resulted in an increase in notes receivables in the current year compared to prior period . we expect that continued low interest rates will significantly limit our interest income in the near term . income tax expense ( benefit ) . income tax benefit for the year ended december 31 , 2016 was $ 896 thousand . income tax expense for the year ended december 31 , 2015 was $ 36,314 thousand . net loss . net loss for the years ended december 31 , 2016 and 2015 was $ 63,937 thousand and $ 50,074 thousand , respectively . the increase in net loss is mainly attributable to the expanded research and development activities , and an increase in acquired in-process research and development and general and administrative activities . comparison of the years ended december 31 , 2015 and 2014 revenues . revenues were $ 4,590 thousand for the year ended december 31 , 2015 , as compared to $ 3,825 thousand for the year ended december 31 , 2014. the net increase of $ 765 thousand is primarily due to an increase in activities under our active grants for the year ended december 31 , 2015 compared to the corresponding period of 2014 due primarily to an increase in active grants in the year ending december 31 , 2015. sales and service revenues generated from the sale of customized reagents and providing contract development services decreased $ 277 thousand for the year ended december 2015 as compared to the same period of 2014. in june 2012 , we were awarded a third advanced technology sttr grant , with an initial award of $ 300 thousand , to support our program to generate and develop novel human antibody therapeutics to combat staph infections , including methicillin-resistant staph ( the “ staph grant ii award ” ) . the project period for the staph grant ii award covered a two-year period which commenced in june 2012 , with a total grant award of $ 600 thousand . the staph grant ii award revenues for the years ended december 31 , 2015 , 2014 and 2013 , were $ 0 , $ 150 thousand and $ 308 thousand , respectively . in june 2014 , the niaid , a division of the nih awarded us the staph grant iii award , a phase ii sttr grant to support the advanced preclinical development of human bispecific antibody therapeutics to prevent and treat staph infections , including mrsa . the project period for the staph grant iii award covered a two-year period which commenced in june 2014 , with total funds available of approximately $ 1 million per year for up to 2 years . during the years ended december 31 , 2015 and 2014 , we recorded $ 884 thousand and $ 220 thousand of revenue , respectively , associated with the staph grant iii award . 55 in june 2014 , we were awarded the phase i sttr grant award , a phase i sttr grant entitled “ anti-pseudomonas immunotherapy and targ eted drug delivery ” from the niaid . the phase i sttr grant award was to support the preclinical development of novel anti- pseudomonas aeruginosa mab immunotherapy or an antibody-mediated targeted antibiotic delivery vehicle . each modality may be an effecti ve and safe stand-alone therapy and or a component of a “ cocktail ” therapeutic option for prevention and treatment of p. aeruginosa infections . the project period for the phase i sttr grant award covered a two-year period which commenced in july 2014 , with total funds available of approximately $ 300 thousand per year for up to 2 years . during the years ended december 31 , 2015 and 2014 , we recorded $ 302 thousand and $ 28 thousand of revenue , respectively , associated with the phase i sttr grant award . in july 2014 , we were awarded the phase i myc grant award , a phase i sttr grant from the nci , a division of the nih , entitled “ targeting of myc-max dimerization for the treatment of cancer ” . the phase i myc grant award was to support the preclinical development of the myc inhibitor , which interferes with the ppi between myc and its obligatory dimerization partner , max , preventing sequence-specific binding to dna and subsequent initiation of oncogenic transformation . the project period for the phase i myc grant award covered a one-year period which commenced in august 2014 , with total funds available of approximately $ 225 thousand . during the years ended december 31 , 2015 and 2014 , we recorded $ 139 thousand and $ 86 thousand of revenue , respectively

cash flows from investing activities . net cash used for investing activities was $ 17.5 million for 2016 as compared to cash provided of $ 12.6 million for 2015. the net cash provided related primarily to purchases of investments of $ 6.0 million and fixed assets of $ 6.9 million . we expect to increase our investment in equipment as we seek to expand and progress our research and development capabilities . cash flows from financing activities . net cash provided by financing activities was $ 131.7 million for 2016 , which was primarily from the net proceeds from the issuance of common stock and the loan and security agreement and proceeds from the issuance of common stock , partially offset by cash payments for treasury shares . future liquidity needs . we have principally financed our operations through underwritten public offerings and private equity financings with aggregate net proceeds of $ 153.4 million , as we have not generated any product related revenue from our principal operations to date , and do not expect to generate significant revenue for several years , if ever . we will need to raise additional capital before we exhaust our current cash resources in order to continue to fund our research and development , including our plans for clinical and preclinical trials and new product development , as well as to fund operations generally . as and if necessary , we will seek to raise additional funds through various potential sources , such as equity and debt financings , or through corporate collaboration and license agreements . we can give no assurances that we will be able to secure such additional sources of funds to support our operations , or , if such funds are available to us , that such additional financing will be sufficient to meet our needs .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows from investing activities . net cash used for investing activities was $ 17.5 million for 2016 as compared to cash provided of $ 12.6 million for 2015. the net cash provided related primarily to purchases of investments of $ 6.0 million and fixed assets of $ 6.9 million . we expect to increase our investment in equipment as we seek to expand and progress our research and development capabilities . cash flows from financing activities . net cash provided by financing activities was $ 131.7 million for 2016 , which was primarily from the net proceeds from the issuance of common stock and the loan and security agreement and proceeds from the issuance of common stock , partially offset by cash payments for treasury shares . future liquidity needs . we have principally financed our operations through underwritten public offerings and private equity financings with aggregate net proceeds of $ 153.4 million , as we have not generated any product related revenue from our principal operations to date , and do not expect to generate significant revenue for several years , if ever . we will need to raise additional capital before we exhaust our current cash resources in order to continue to fund our research and development , including our plans for clinical and preclinical trials and new product development , as well as to fund operations generally . as and if necessary , we will seek to raise additional funds through various potential sources , such as equity and debt financings , or through corporate collaboration and license agreements . we can give no assurances that we will be able to secure such additional sources of funds to support our operations , or , if such funds are available to us , that such additional financing will be sufficient to meet our needs .
```    
 Suspicious Activity Report : separately , under the terms of the joint venture agreement , yuhan contributed an initial investment of $ 10.0 million to immuneoncia , and we granted immuneoncia an exclusive license to one of our immune checkpoint antibodies for specified countries while retaining the rights for the u.s. , european and japanese markets , as well as global rights for immuneoncia to two additional antibodies that will be selected by immuneoncia from a group of pre-specified antibodies from our immuno-oncology antibody portfolio . yuhan owns 51 % of immuneoncia , while we own 49 % . 3sbio term sheet in june 2016 , we and tnk entered into a binding term sheet with shenyang sunshine pharmaceutical company ltd ( “ 3sbio ” ) , a china based company , to form a joint venture to develop and commercialize proprietary immunotherapies , including those developed from , including or using tnk 's car-t technology targeting cea positive cancers . due diligence and negotiations between 3sbio and us for the definitive agreement ( s ) are currently ongoing . in june 2016 , 3sbio purchased $ 10.0 million of common stock and warrants as part of our private placement offering . servier license and collaboration agreement in july 2016 , we announced a license and collaboration agreement with les laboratoires servier , sas , a corporation incorporated under the laws of france , and institut de recherches internationales servier , a company duly organized and existing under the laws of france ( individually and collectively , “ servier ” ) for the development , manufacture and commercialization of products using our fully human immuno-oncology anti-pd-1 mab sti-a1110 . the financial terms of the agreement include , among other things , a non-refundable upfront payment to sorrento of 25 million , or $ 27.4 million , which we received in july 2016. we may also receive development milestone payments for the initial product and each additional product . we may receive up to 710 million in various payments based on commercial sales milestones related to annual net sales levels for the initial product and then also for each additional product . in addition to the commercial sales milestones , we will be entitled to receive variable royalties on the sales of all commercialized products ranging from high single-digit to double-digit percentages . during the twelve months ended december 31 , 2016 , we recognized $ 3.8 million in license fee revenue pursuant to the agreement . cha biotech term sheet in august 2016 , we announced a binding term sheet to create a joint venture ( the “ jv ” ) with cha biotech co. , ltd. ( “ cbt ” ) of south korea to develop and commercialize proprietary car modified cellular therapies based on cbt 's activated killer cell ( “ akc ” ) technology in combination with five of our cars for all disease conditions , including oncology and infectious diseases . the jv will cover products on a global basis with the exception of the greater chinese market , which includes mainland china , hong kong , macau and taiwan . in addition , we will obtain an exclusive license to develop and commercialize cbt 's novel investigator-initiated trial stage akc technology in major territories , including the united states and europe , and with a co-exclusive license in china . under the terms of the term sheet , we and cbt will make contributions of $ 2 million to the jv , and we will grant the jv an 51 exclusive license to five cars solely for combination with the akc technology , while cbt will contribute its akc technology . cbt will initi ally own 51 % of the jv while we will initially hold the remaining 49 % . we , under a royalty bearing license , will also gain access to the akc technology for the use outside the jv alone or with any other of our product candidates . due diligence and negotiat ions between cbt and us for the definitive agreement ( s ) are currently ongoing . however , the binding term sheet is currently terminable by either party at will and no assurances can be made that the transaction will be completed . scilex acquisition on november 8 , 2016 , we entered into a stock purchase agreement with scilex pharmaceuticals inc. ( “ scilex ” ) and a majority of the stockholders of scilex ( the “ scilex stockholders ” ) pursuant to which we acquired from the scilex stockholders approximately 72 % of the outstanding capital stock of scilex . scilex 's lead product candidate , ztlido , is a next-generation lidocaine patch currently in development for the treatment of postherpetic neuralgia ( “ phn ” ) , a severe neuropathic pain condition . ztlido is manufactured by our collaboration partner in their state of the art manufacturing facility . celularity transaction in november 2016 , we entered into a non-binding term sheet between us , our subsidiary , tnk , and celularity , inc. ( “ celularity ” ) , a research and development company , setting forth the terms and conditions by which we or tnk with one or more third parties would contribute certain assets to celularity ( the “ celularity transaction ” ) . in addition , at this time , we loaned $ 5.0 million to celularity pursuant to a promissory note issued to us ( the “ celularity note ” ) . pursuant to the terms of the celularity note , the loan will be due and payable in full on the earlier of november 1 , 2017 and the occurrence of an event of default under the celularity note ( the “ maturity date ” ) . the celularity note also provides that , in certain circumstances , we shall loan celularity up to an additional $ 5.0 million over the next 12 months . story_separator_special_tag gain on derivative liability for the year ended december 31 , 2016 was $ 5,520 thousand compared to a loss on derivative liability of $ 3,360 thousand for the year ended december 31 , 2015. the increase in the year ended december 31 , 2016 as compared to the same period in 2015 is due to the expiration of the unexercised derivative liability on march 31 , 2016 associated with the cancelled call option on shares of nantkwest , inc. stock . gain or loss on equity investments . gain on equity investments for the year ended december 31 , 2016 was $ 435 thousand compared to a loss on equity investments of $ 4,041 thousand for the year ended december 31 , 2015. the increase was primarily due to the recognition of our portion of the loss from operations from our joint venture entities which did not exist during the same period in 2015. interest expense . interest expense for the years ended december 31 , 2016 and 2015 was $ 1,610 thousand and $ 1,652 thousand , respectively . interest income . interest income for the years ended december 31 , 2016 and 2015 was $ 272 thousand and $ 24 thousand , respectively . the increase in interest income resulted in an increase in notes receivables in the current year compared to prior period . we expect that continued low interest rates will significantly limit our interest income in the near term . income tax expense ( benefit ) . income tax benefit for the year ended december 31 , 2016 was $ 896 thousand . income tax expense for the year ended december 31 , 2015 was $ 36,314 thousand . net loss . net loss for the years ended december 31 , 2016 and 2015 was $ 63,937 thousand and $ 50,074 thousand , respectively . the increase in net loss is mainly attributable to the expanded research and development activities , and an increase in acquired in-process research and development and general and administrative activities . comparison of the years ended december 31 , 2015 and 2014 revenues . revenues were $ 4,590 thousand for the year ended december 31 , 2015 , as compared to $ 3,825 thousand for the year ended december 31 , 2014. the net increase of $ 765 thousand is primarily due to an increase in activities under our active grants for the year ended december 31 , 2015 compared to the corresponding period of 2014 due primarily to an increase in active grants in the year ending december 31 , 2015. sales and service revenues generated from the sale of customized reagents and providing contract development services decreased $ 277 thousand for the year ended december 2015 as compared to the same period of 2014. in june 2012 , we were awarded a third advanced technology sttr grant , with an initial award of $ 300 thousand , to support our program to generate and develop novel human antibody therapeutics to combat staph infections , including methicillin-resistant staph ( the “ staph grant ii award ” ) . the project period for the staph grant ii award covered a two-year period which commenced in june 2012 , with a total grant award of $ 600 thousand . the staph grant ii award revenues for the years ended december 31 , 2015 , 2014 and 2013 , were $ 0 , $ 150 thousand and $ 308 thousand , respectively . in june 2014 , the niaid , a division of the nih awarded us the staph grant iii award , a phase ii sttr grant to support the advanced preclinical development of human bispecific antibody therapeutics to prevent and treat staph infections , including mrsa . the project period for the staph grant iii award covered a two-year period which commenced in june 2014 , with total funds available of approximately $ 1 million per year for up to 2 years . during the years ended december 31 , 2015 and 2014 , we recorded $ 884 thousand and $ 220 thousand of revenue , respectively , associated with the staph grant iii award . 55 in june 2014 , we were awarded the phase i sttr grant award , a phase i sttr grant entitled “ anti-pseudomonas immunotherapy and targ eted drug delivery ” from the niaid . the phase i sttr grant award was to support the preclinical development of novel anti- pseudomonas aeruginosa mab immunotherapy or an antibody-mediated targeted antibiotic delivery vehicle . each modality may be an effecti ve and safe stand-alone therapy and or a component of a “ cocktail ” therapeutic option for prevention and treatment of p. aeruginosa infections . the project period for the phase i sttr grant award covered a two-year period which commenced in july 2014 , with total funds available of approximately $ 300 thousand per year for up to 2 years . during the years ended december 31 , 2015 and 2014 , we recorded $ 302 thousand and $ 28 thousand of revenue , respectively , associated with the phase i sttr grant award . in july 2014 , we were awarded the phase i myc grant award , a phase i sttr grant from the nci , a division of the nih , entitled “ targeting of myc-max dimerization for the treatment of cancer ” . the phase i myc grant award was to support the preclinical development of the myc inhibitor , which interferes with the ppi between myc and its obligatory dimerization partner , max , preventing sequence-specific binding to dna and subsequent initiation of oncogenic transformation . the project period for the phase i myc grant award covered a one-year period which commenced in august 2014 , with total funds available of approximately $ 225 thousand . during the years ended december 31 , 2015 and 2014 , we recorded $ 139 thousand and $ 86 thousand of revenue , respectively

